schizophrenia. schizophrenia
Conditions
Interventions
Intervention 1: Tablets Risperidone (6 mg/day) combined with 325 mg/day Acetaminophen as intervention group for 8 weeks. Intervention 2: Tablet Risperidone (6 mg/day) combined with placebo as control
Treatment - Drugs
Placebo
Tablets Risperidone (6 mg/day) combined with 325 mg/day Acetaminophen as intervention group for 8 weeks
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria:1-Diagnosis of Schizophrenia based on DSM-5 criteria;2- Minimum Score of 60 on Positive and Negative Scale 3- Age between 18-55; 4- chronic Schizophrenia- duration of the disorder more than 2 years; ; 6-Minimum score of 20 in negative suscale Exclusion Criteria:1-any other major mental disorder based on DSM-5; 2-Any serious medical or neurological problem; 3- IQ less than 70;4- Substance dependence during the last 6 months(except for nicotine and caffeine) 5-receiving oral antipsychotic medications during the last week or receiving any depot antipsychotic medication during the last month; ;6-receiving ECT during the last 14 days,7-hepatic and renal disease; 7- history of abnormal bleeding
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-8 after beginig of treatment. Method of measurement: by Positive and Negative Symptoms Scale(PANSS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Extrapyramidal side effects. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: by Extrapyramidal Symptoms Rating Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactProf. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed